Latest research
Latest corporate research
Latest tax advantaged reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax advantaged research
Product reports for investors and advisors
Latest published research
Blackfinch Investments (Fund)
Blackfinch Ventures EIS Portfolios
2nd Dec 2024
Calculus Capital (Funds)
Calculus Knowledge Intensive EIS Fund 3
29th Nov 2024
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Bespoke valuation services
Bespoke valuation services
Services for clients with specific needs
Services for funds
Tax advantaged research
Product reports for investors and advisors.
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
108: An all-star panel discuss EIS & VCTs in 2024 and look forward to 2025
Stay up-to-date with the latest research
Sign up to our newsletter
Latest Update
Our research can be accessed for free under MIFID.
Find out more >
All sectors
Agriculture
Building & Construction
Consumer
Financials
Industrial
Infrastructure
Investment Companies
Life Sciences
Media
Mining
Oil & Gas
Property
Renewables
Services
Technology
Transportation
Utilities
list companies
City of London Investment Group
Financials
H1 results confirm dividend cover
By
Dr Brian Moretta
20 Feb 2017
Collagen Solutions Plc
Life Sciences
Capital increase to support accelerated growth
By
Dr Martin Hall
14 Feb 2017
Stay up-to-date with the latest research
Sign up to our newsletter
Allergy Therapeutics plc
Life Sciences
Disruptive peanut allergy vaccine
By
Dr Martin Hall
13 Feb 2017
Alliance Pharma Plc
Life Sciences
Potential of Diclectin
By
Dr Martin Hall
25 Jan 2017
City of London Investment Group
Financials
Q2 statement shows robust profitability
By
Dr Brian Moretta
24 Jan 2017
Allergy Therapeutics plc
Life Sciences
Investment driving market share gains
By
Dr Martin Hall
20 Jan 2017
Diurnal Group Plc
Life Sciences
Infacort® – On track to market
By
Dr Martin Hall
19 Jan 2017
City of London Investment Group
Financials
Swings and roundabouts
By
Dr Brian Moretta
06 Jan 2017
Prev
1
...
28
29
30
